A sophisticated investor who turned 91 this year recently complained to Chanticleer about a pressing problem in his share portfolio caused by the international blood products company CSL.
“I bought these in the IPO and now I can’t sell them – the capital gains would kill me,” he said without a hint of irony.
Loading...
Tony Boyd is the former Chanticleer columnist. He has more than 35 years' experience as a finance journalist. Connect with Tony on Twitter. Email Tony at tony.boyd@afr.com
